Ovarian Cancer – Treatment.
By Dominique Fontanilla, Senior Analyst
16 May 2014
I joined Datamonitor Healthcare’s disease team in 2014 having previously worked as a biochemistry postdoctoral fellow ...
Read full bio
Despite high responses to initial treatment for ovarian cancer, the majority of patients will eventually relapse with incurable disease. Datamonitor Healthcare conducted a survey of 224 medical oncologists in the US, Japan and five major EU markets (France, Germany, Italy, Spain and the UK) to explore the treatment of ovarian cancer.
What do you get from this module?
- Access an analysis of current prescribing patterns, as surveyed from 224 medical oncologists, allowing you to gain an in depth understanding of treatment decision making.
- Explore the challenges of treating ovarian cancer.
- Identify unmet needs, allowing you to make the most of opportunities available to you and your business.
Key questions answered
- Which stage of the disease currently has the highest proportion of ovarian cancer patients?
- Is there a distinct difference between the distribution of ovarian cancer patients across the US, Japan and five major EU markets?
- What are the leading therapies to treat each stage of ovarian cancer?
- What is needed to improve outcomes in ovarian cancer?
- What are the leading therapies to treat patients with recurrent or platinum-resistant ovarian cancer?